Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Today's H2S ... Thought of the Day !

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Oct 03, 2022 9:42pm

195 Views

Post# 35003049

RE:RE:Today's H2S ... Thought of the Day !

Yes Sir Bagger !

Let me put it this way ... what you see isn't necessarily what you get with H2S.

Sure there are specific purposes for the active ingredients used (like Naproxen) but then you have a whole slew of potential benefits.

All about "how" you use it - DNA repair, protecting cells from damage, even slowing down the aging process.

Healthier people with fewer medical issues.

The key though - we need a first win and hopefully with the acute product.
Everything else depends on a first win.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec